SCHEMBL4152460

SCHEMBL4152460

Cc1ccc2c(c1)c1c3n2CCCNC3CCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 1.00
MEN1 O00255 6/20 0.88
KMT2A Q03164 6/20 0.88
KDM4E B2RXH2 6/20 0.88
CYP1A2 P05177 3/20 0.88
CYP2D6 P10635 3/20 0.88
TP53 P04637 3/20 0.88
CYP3A4 P08684 2/20 0.88
TEAD4 Q15561 2/20 0.88
HTR1A P08908 1/20 0.88
ADRA2A P08913 1/20 0.88
CHRM1 P11229 1/20 0.88
MAOA P21397 1/20 0.88
DRD1 P21728 1/20 0.88
SLC6A2 P23975 1/20 0.88
TEAD1 P28347 1/20 0.88
SLC6A4 P31645 1/20 0.88
SLC6A3 Q01959 1/20 0.88
KCNH2 Q12809 1/20 0.88
TEAD2 Q15562 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pirlindole SCHEMBL29500947 0.94 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL373564 0.94 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL18878061 0.94 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL18877133 0.94 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL4157397 0.93 HSD17B10 (0.97) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL1649683 0.91 HSD17B10 (0.95) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL3761340 0.86 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL30984462 0.86 HSD17B10 (1.00) HSD17B10MEN1KMT2AKDM4ECYP1A2
Pirlindole SCHEMBL17241165 0.78 HSD17B10 (0.68) HSD17B10MEN1KMT2AKDM4ECYP1A2
SCHEMBL13702963 0.77 KMT2A (0.98) HSD17B10MEN1KMT2AKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR HSD17B10 1367/4885MEN1 4608/4885KMT2A 3806/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR HSD17B10 1367/4885MEN1 4608/4885KMT2A 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.